Transfusion Medicine and Hemotherapy最新文献_第5页

Two Cases of Anti-D Alloimmunization in D-Negative Thai Patients as a Result of the Asian-Type DEL on Transfused Red Cells 两例泰国d阴性患者因输注红细胞出现亚洲型DEL而产生抗d异体免疫

4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-09-14 DOI: 10.1159/000533625

Kanyapon Suksard, Komon Luangtrakool, Thongbai Rungroung, Sutthisak Chamsai, Pradermchai Saetam, Kulvara Kittisares, Parichart Permpikul, Janejira Kittivorapart

{"title":"Two Cases of Anti-D Alloimmunization in D-Negative Thai Patients as a Result of the Asian-Type DEL on Transfused Red Cells","authors":"Kanyapon Suksard, Komon Luangtrakool, Thongbai Rungroung, Sutthisak Chamsai, Pradermchai Saetam, Kulvara Kittisares, Parichart Permpikul, Janejira Kittivorapart","doi":"10.1159/000533625","DOIUrl":"https://doi.org/10.1159/000533625","url":null,"abstract":"Introduction: DEL is known to be one of the weakest D variants, which can be detected by the adsorption-elution technique or by molecular study. Currently, in Thailand, we do not routinely test for DEL variants serologically or genetically among serologic RhD-negative blood donors. Case Presentation: We reported 2 cases of alloimmunization after transfused with Rh DEL, RHD*DEL1 allele, in the Thai population. The first case was a 73-year-old male with anemia who presented with post-cardiac arrest and septic shock. The patient was group B, RhD-negative, and was transfused with RhD-negative red blood cells (RBCs). Antibody screening and identification found that the patient developed anti-D and anti-Mia during the admission course. The second case was a 38-year-old woman with pseudomyxoma peritonei who developed anti-D after receiving four units of RhD-negative RBCs during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Both patients did not receive anti-D immunoglobulin and had no previous history of anti-D detection. We retrospectively investigated and found two units of RHD*DEL1 among the RBCs transfused to these patients. Discussion: Previous reports of several cases of anti-D alloimmunization in RhD-negative recipients transfused by RHD*DEL1, an Asian-type DEL, are limited only to East Asia. We first identified 2 patients with anti-D alloimmunization after receiving the RHD*DEL1 RBCs in the Thai population. This raises concern about Rh DEL screening among D-negative Thai blood donors and whether to remove DEL units from the D-negative inventory to improve patient safety.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134973087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moleculargenetic and in Addition Partly Discrepant Infection Serological Malaria Testing in Two Blood Donors 两名献血者的分子遗传学和部分差异感染血清学疟疾检测

4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-09-11 DOI: 10.1159/000530141

Lutz Pichl, Katja Konietzko, Ludwig Hartmann, Bogdan Puscasu, Carlos Jiménez Klingberg

{"title":"Moleculargenetic and in Addition Partly Discrepant Infection Serological Malaria Testing in Two Blood Donors","authors":"Lutz Pichl, Katja Konietzko, Ludwig Hartmann, Bogdan Puscasu, Carlos Jiménez Klingberg","doi":"10.1159/000530141","DOIUrl":"https://doi.org/10.1159/000530141","url":null,"abstract":"Introduction: According to the guidelines (GL) valid in Germany, persons born or raised in a malaria-endemic area or had continuously stayed in a malaria-endemic area for more than 6 months may only be admitted donating blood if, among other things, validated and quality-assured laboratory diagnostics show that there is no evidence of infectivity. In a statement of the Working Group \"Blood\" of the Federal Ministry of Health (WGB), a reduction of the deferral period from 4 to 3 years and an antibody test after the deferral period are recommended. Methods: In accordance with the GL, nucleic acid testing (NAT) by means of PCR is carried out at our institution after a retention period of 4 years. In addition to the validated molecular biological testing, an infection serological examination was performed. Case Presentation: In the present cases, Plasmodia genome was detected in the respective single PCR in two blood donors originating from malaria-endemic areas after the expiry of the deferral period. However, one donor tested negative for antibodies against Plasmodia. Discussion/Conclusion: This observation is discussed in the context of a recommendation of the WGB. The question is addressed whether PCR testing is dispensable or whether a combination of infection serological testing and NAT should be favored.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135938063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stem Cell Mobilization, Collection, and Processing. 干细胞动员、收集和处理。

IF 1.9 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-09-05 eCollection Date: 2023-10-01 DOI: 10.1159/000533649

Katharina Kriegsmann, Patrick Wuchter

引用次数: 0

56. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e. V. (DGTI), 20.–22. September 2023, Berlin, ABSTRACTS 56.德国输血医学和免疫血液学学会年会，20-22。2023年9月，柏林，摘要

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-09-01 DOI: 10.1159/000533306

引用次数: 1

Prelims 预备考试

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-09-01 DOI: 10.1159/000533229

引用次数: 0

Validation of a Parvovirus B19 NAT Assay for Screening of Umbilical Cord Blood for Allogenic Hematopoietic Stem Cell Donation 细小病毒B19 NAT检测筛选脐带血供同种异体造血干细胞捐献的验证

4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-08-30 DOI: 10.1159/000532073

Philipp Steininger, Klaus Korn, Holger Hackstein, Erwin F. Strasser

{"title":"Validation of a Parvovirus B19 NAT Assay for Screening of Umbilical Cord Blood for Allogenic Hematopoietic Stem Cell Donation","authors":"Philipp Steininger, Klaus Korn, Holger Hackstein, Erwin F. Strasser","doi":"10.1159/000532073","DOIUrl":"https://doi.org/10.1159/000532073","url":null,"abstract":"Introduction: Parvovirus B19 transmitted by umbilical cord blood (UCB) products may cause severe disease in allogenic hematopoietic stem cell transplant recipients. Thus, commercially available nucleic acid test (NAT) assays for highly sensitive detection of parvovirus B19 DNA validated for the specimen cord blood plasma (CBP) are required to avoid parvovirus B19 transmission by umbilical hematopoietic stem cell preparations. Methods: The multiplex cobas DPX NAT assay was validated for detection of parvovirus B19 DNA in CBP derived from citrate anticoagulated UCB units which have been processed by the Rubinstein method. In total, 363 retained CBP samples pretested negative for parvovirus B19 DNA were prepared for analyzing sensitivity, specificity, and interference of that NAT assay. The 3rd WHO International Standard for parvovirus B19 DNA was used for determining the 95% limit of detection (LOD95) by probit analysis. Results: The validation of the parvovirus B19 NAT assay for CBP demonstrated high sensitivity, specificity, intra- and inter-assay precision. Dilution series and replicate analyses showed a high linearity of the assay with a coefficient of determination above 0.99 and revealed a LOD95 of 17 International Units (IU)/mL (95% confidence interval, 14–44 IU/mL) for parvovirus B19 DNA in CBP samples. Conclusion: The validation of a commercially available parvovirus B19 NAT assay for the specimen CBP demonstrated a high assay performance fulfilling German guidelines and international regulations.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136241931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets 高效嵌合抗原受体t细胞生成开始与白细胞诱导系统室的血小板分离装置

4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-08-30 DOI: 10.1159/000532130

Stefani Xhaxho, Linping Chen-Wichmann, Sophie Kreissig, Roland Windisch, Adrian Gottschlich, Sayantan Nandi, Sophie Schabernack, Irmgard Kohler, Christian Kellner, Sebastian Kobold, Andreas Humpe, Christian Wichmann

{"title":"Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets","authors":"Stefani Xhaxho, Linping Chen-Wichmann, Sophie Kreissig, Roland Windisch, Adrian Gottschlich, Sayantan Nandi, Sophie Schabernack, Irmgard Kohler, Christian Kellner, Sebastian Kobold, Andreas Humpe, Christian Wichmann","doi":"10.1159/000532130","DOIUrl":"https://doi.org/10.1159/000532130","url":null,"abstract":"Introduction: Primary human blood cells represent an essential model system to study physiology and disease. However, human blood is a limited resource. During healthy donor plateletpheresis, the leukoreduction system chamber (LRSC) reduces the leukocyte amount within the subsequent platelet concentrate through saturated, fluidized, particle bed filtration technology. Normally, the LRSC is discarded after apheresis is completed. Compared to peripheral blood, LRSC yields 10-fold mononuclear cell concentration. Methods: To explore if those retained leukocytes are attractive for research purposes, we isolated CD3+ T cells from the usually discarded LRSCs via density gradient centrifugation in order to manufacture CD19-targeted chimeric antigen receptor (CAR) T cells. Results: Immunophenotypic characterization revealed viable and normal CD4+ and CD8+ T-cell populations within LRSC, with low CD19+ B cell counts. Magnetic-activated cell sorting (MACS) purified CD3+ T cells were transduced with CD19 CAR-encoding lentiviral self-inactivating vectors using concentrated viral supernatants. Robust CD19 CAR cell surface expression on transduced T cells was confirmed by flow cytometry. CD19 CAR T cells were further enriched through anti-CAR MACS, yielding 80% CAR+ T-cell populations. In vitro CAR T cell expansion to clinically relevant numbers was achieved. To prove functionality, CAR T cells were co-incubated with the human CD19+ B cell precursor leukemia cell line Nalm6. Compared to unmodified T cells, CD19 CAR T cells effectively eradicated Nalm6 cells. Conclusion: Taken together, we can show that lymphocytes isolated from LRSCs of plateletpheresis sets can be efficiently used for the generation of functional CAR T cells for experimental purposes.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136241928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation. 骨髓瘤患者自体造血细胞移植的动员策略。

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-08-24 eCollection Date: 2023-10-01 DOI: 10.1159/000531940

Esa Jantunen, Anu Partanen, Antti Turunen, Ville Varmavuo, Raija Silvennoinen

{"title":"Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.","authors":"Esa Jantunen, Anu Partanen, Antti Turunen, Ville Varmavuo, Raija Silvennoinen","doi":"10.1159/000531940","DOIUrl":"https://doi.org/10.1159/000531940","url":null,"abstract":"Background: Multiple myeloma is currently the leading indication for autologous hematopoietic cell transplantation (AHCT). A prerequisite for AHCT is mobilization and collection of adequate blood graft to support high-dose therapy. Current mobilization strategies include granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy most commonly cyclophosphamide (CY). More recently, plerixafor has become into agenda especially in patients who mobilize poorly. In the selection of a mobilization method, several factors should be considered.Summary: Preplanned collection target is important as G-CSF plus plerixafor is more effective in the mobilization of CD34+ cells than G-CSF alone. On the other hand, CY plus G-CSF is superior to G-CSF only mobilization. Previous therapy and age of the patients are important considerations as G-CSF alone may not be effective enough in patients with risk factors for poor mobilization. These factors include extensive lenalidomide exposure, irradiation to bone marrow-bearing sites, higher age, or a previous mobilization failure. Also, local preferences and experiences as well as the number of apheresis needed are important issues as well as cost-effectiveness considerations. Mobilization method used may have implication for cellular composition of collected grafts, which might have an impact on posttransplant events such as hematologic and immune recovery in addition to also potential long-term outcomes.Key message: Currently, G-CSF alone and preemptive plerixafor if needed might be considered as a standard mobilization strategy in MM patients intended for AHCT.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"50 5","pages":"438-447"},"PeriodicalIF":2.2,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71414021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CD34⁺ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients. CD34+细胞动员、自体移植物细胞组成和套细胞淋巴瘤患者的预后。

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-08-23 eCollection Date: 2023-10-01 DOI: 10.1159/000531799

Antti Samuli Turunen, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Minna Harmanen, Leena Keskinen, Pentti Mäntymaa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen, Anu Partanen

{"title":"CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.","authors":"Antti Samuli Turunen, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Minna Harmanen, Leena Keskinen, Pentti Mäntymaa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen, Anu Partanen","doi":"10.1159/000531799","DOIUrl":"https://doi.org/10.1159/000531799","url":null,"abstract":"Backgound: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.Study design and methods: This prospective multicenter study evaluated the impact of CD34+ cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.Results: During CD34+ cell mobilization, a higher blood CD34+ cell count (>30 × 106/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, p = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34+ cells (>3.0 × 106/kg) was associated with faster platelet (median 11 vs. 15 days, p = 0.03) and neutrophil (median 9 vs. 10 days, p = 0.02) recovery posttransplant. Very low graft CD3+CD8+ cell count (≤10 × 106/kg) correlated with worse progression-free survival (PFS) (HR 4.136, 95% CI 1.547-11.059, p = 0.005). On the other hand, higher absolute lymphocyte count >2.5 × 109/L at 30 days after ASCT (ALC-30) was linked with better PFS (median NR vs. 99 months, p = 0.045) and overall survival (median NR in either group, p = 0.05).Conclusions: Better mobilization capacity and higher graft CD3+CD8+ cell count had a positive prognostic impact in this study, in addition to earlier lymphocyte recovery (ALC-30>2.5 × 106/L). These results need to be validated in another study with a larger patient cohort.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"50 5","pages":"428-437"},"PeriodicalIF":2.2,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71414016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia 急性淋巴细胞白血病患者四次CAR-T细胞桥接两次同种异体造血干细胞移植治疗

4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2023-08-22 DOI: 10.1159/000531681

Qing Zhang, Yi Dong, Zhimin Zhai, Qianshan Tao

引用次数: 0